Introduction Steroid-refractory graft-versus-host disease (SR-GvHD) after hematopoietic stem cell transplantation (HSCT) remains a major cause of morbidity and mortality [1, 2]. The REACH trials demonstrated a better overall response and a better failure free survival in patients treated with the JAK inhibitor ruxolitinib for acute and chronic SR-GvHD compared to standard of care [3,4,5].
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Kai
Contact Kai, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack